By Michael Susin GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary endpoint of progression-free survival. The Read more
Tag: endpoint
GSK respiratory syncytial virus vaccine Phase 3 trial meets primary endpoint
GSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine candidate for adults aged over 60 years met its primary endpoint. The U.K.-based maker of Read more